The specialised tissue at the back of the eye, known as the retina, captures light and transmits a signal to the brain to allow for the sensation of vision. Remarkably, the central area (4%) of the retina, known as the macula, is responsible for up to 90% of our vision and all of our colour vision. Nutritional pigments, known as carotenoids, are concentrated in the macula where they are known as macular pigment. The three carotenoids which make up macular pigment are meso-zeaxanthin lutein, and zeaxanthin. This pigment plays a vital role for human vision because it optimises the use of light at the macula (via its short wavelength light-filtering properties) and keeps the macula healthy (via its antioxidant properties).
The number of presbyopes continue to rise, but currently only 46% of presbyopes are fitted with a contact lens option. By 2020, the number of presbyopes in the U.S. is expected to reach 123 million, creating a tremendous market opportunity for optometrists who provide multifocal contact lens options. At the same time, the demand for 1-day lenses continues to rise as do the number of silicone hydrogel 1 day lens fits. With a full family of 1-day SiHy options, clariti® 1 day enables you to take advantage of this growing market segment and fit your presbyopic patients with a lens that is convenient, highly oxygen transmissible, and affordable.
Of all the specialties, ophthalmology practices have been hit the hardest in terms of diagnostic code changes. The grand total comes in at just over 100 updates, so we’ve got a lot of ground to cover!
In addition to new neoplasm codes, you’ll have several more options for disorders of the eyelid, lacrimal system, and orbit — including paralytic ectropion, cicatricial lagophthalmos, rosacea conjunctivitis, meibomian gland dysfunction, and others. As with most code changes this year, CMS is aiming at greater specificity.
For more, read on at CodingInstitute.com:
Bringing physicians together with entrepreneurs and industry can generate some clear insights.
Preeya Gupta, MD, of Duke University Eye Center, led a conversation called “Evolution of the Dry Eye Market” at October’s Ophthalmology Innovation Summit, held just prior to the annual meeting of the American Academy of Ophthalmology.
Here are five distinct takeaways delivered by the panel.
Develop for the Markets of Tomorrow
Before he was chairman of Oyster Point Pharmaceuticals, Michael Ackermann, PhD, worked with a team developing an implantable device. It looked promising, but it was expensive. The team decided to abandon the program, realizing that it was no longer realistic to think the device would receive a high- dollar CPT code to cover the cost of the procedure. “Where I think that’s really relevant today is that we need to remember we’re not developing for what the market is now, we’re developing for the market that we’re going to be launching into, and the market that we’re going to be competing in for years to come,” he said.
Innovation Begets Innovation
Caroline Blackie, OD, PhD, medical director, ocular surface disease at Johnson & Johnson Vision Care, said successful innovation can provide an opportunity to change the way medicine is practiced, to have a profound effect on patients’ lives. In a previous position at TearScience, she saw that there was a significant lack of clarity over not only why meibomian gland dysfunction should be seen as important, but even what it was. The company realized that it was extremely unlikely that doctors would physically manipulate the gland to evacuate stagnant content, for rehabilitation. So, the firm innovated a device that would perform that function. What no one expected was that because the technology worked, a number of other device treatments now exist with an add-on manual expression of the gland. “So the base point,” she maintained, “is that when you innovate something that truly works, you have the opportunity to change the face of medicine.”
Don’t Skimp on Your Supply Chain
Quinton Oswald, CEO of Notal Vision, added that for venture- backed companies, venture capitalists sometimes think that the chemistry, manufacturing, and controls phase can be done at the end. But that’s not the case, he said. A company should start early on with its supply chain because products can fail at the approval level due to lack of control. “Push very hard on your boards to allow you to invest in that specific area,” Oswald said.
Clinical Trial Design Is Key … and Complicated
Dr. Blackie stated that clinical trial design, whether for a diagnostic or therapeutic product candidate, comes down to knowing what you’re doing, why you’re doing it, and how to measure it. She said the “why” is usually to try to elevate and potentially transform the patient experience. But for the “what” and “how,” there needs to be extreme clarity about what component or components of the ocular surface system are to be affected and perturbed. “As we think about the dry eye patient and how we collect that patient, if we think about the system in general it becomes overwhelmingly complex,” Dr. Blackie continued. “We really need to titrate and drill down to what components of that system we’re looking to address so that we can home in on the appropriate metric.”
Headwinds Are Good
Christian Roesky, MD, PhD, managing director and CEO at Novaliq, said his group encountered resistance to its decision to try to redefine cyclosporine for dry eye disease. People didn’t believe its use could be improved after 10 years on the market, but eventually the treatment succeeded. “We need headwinds,” Dr. Roesky explained. “If we just follow trends, we will not explore something new.” Want to hear more? At the upcoming OIS meeting at SECO, clinical leaders will share their perspective on the latest developments in treating Dry Eye Disease, including predictions on where they see the market going.
The purpose of this exclusive half-day meeting is to showcase ophthalmic innovations under development for the optometric community. The meeting also create opportunities for clinicians and industry professionals to connect and exchange insights on the future of the sector.
This is a must-attend program for any practitioner interested in advancing their practice to the next level. The summit is being conveniently held at the Marriott New Orleans Downtown, across from the Convention Center. Register ASAP and block out your schedule for Thursday, February 21 from noon until 6:00 PM. Go to https://ois.net/ois-seco- 2019/register/ to register.
Lots of press lately related to drug recalls. Two links that you might be interested in are the FDA’s official list of recalled drugs, and RecallGuide.org which will notify you if your specific medication gets recalled. Of course you need to create an account, and enter the meds that you’re on, including manufacturer.
By Vision Trends
Special to SECO University
“Do you take my insurance?” Cue the inward groan we’ve all had. Dealing with vision insurance can be a pain and most of us would rather not, but the fact is, the number of patients walking into an independent optometric practice with vision insurance continues to increase. Vision insurance is here to stay!
However, all is not lost. It is still possible for an independent optometric business owner in today’s eye care and eyewear marketplace to provide its patients with stellar service and high quality eyewear, and even increase its practice profitability with the right insurance strategy.
“Common insurance obstacles can be overcome when a practice steps back and takes a holistic look at the impact insurance has on its practice,” says Michael Toups, OD and President and co-founder of Vision Trends, the nation’s largest independently-owned optometric doctor alliance.